Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2022-01, Vol.23 (1), p.77-90
Hauptverfasser:	Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, Sangro, Bruno
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Aged Antiangiogenic agents Apoptosis Aspartate aminotransferase Cancer Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - psychology Clinical medicine Clinical trials Drug dosages Female Hepatitis Hepatitis C Hepatocellular carcinoma Humans Immunotherapy Inhibitor drugs Life Sciences Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - psychology Male Middle Aged Monoclonal antibodies Nivolumab - adverse effects Nivolumab - therapeutic use Patients Protein-tyrosine kinase Safety Sorafenib - adverse effects Sorafenib - therapeutic use Survival Targeted cancer therapy Toxicity Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!